Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares

Core Viewpoint - Medexus Pharmaceuticals has announced a Normal Course Issuer Bid (NCIB) to repurchase up to 2,983,650 common shares, representing approximately 10% of its public float, as a strategy to enhance shareholder value and stabilize the market for its shares [1][2]. Group 1: NCIB Details - The NCIB will allow Medexus to purchase shares starting from November 24, 2025, until November 23, 2026, or until the maximum number of shares is acquired [2]. - The purchases will be conducted through open market transactions on the Toronto Stock Exchange (TSX) at prevailing market prices, funded by the company's general funds [2][3]. - As of November 12, 2025, Medexus had 32,420,060 common shares outstanding, with a public float of 29,836,506 common shares [1]. Group 2: Trading Volume and Limitations - The average daily trading volume (ADTV) of Medexus's common shares on the TSX for the six months ending October 31, 2025, was 40,066 shares [3]. - Under TSX rules, the maximum number of shares that can be purchased on any trading day is limited to 10,016 shares, which is 25% of the ADTV, excluding block purchases [3]. Group 3: Company Overview - Medexus is a leading specialty pharmaceutical company focused on innovative treatments for rare diseases, particularly in hematology, hematology-oncology, rheumatology, and allergy [4].